SUSTAINED RELEASE FORMULATION AND NANOSTRUCTURED LIPID CARRIER OF METFORMIN HYDROCHLORIDE

• Main Author: Sarnoko, Andriningrum
• Format: Theses
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/54395
• Institution: Institut Teknologi Bandung

Metformin hydrochloride is an oral antihyperglycemic drug in the biguanide class in the therapy of Type 2 Diabetes Mellitus which has a relatively low bioavailability and a short elimination half-life of about 1.5 - 3 hours, so a sustained release preparation is needed to keep the drug concentration in the blood constant. stable. The aim of this study was to produce a sustained release preparation of metformin hydrochloride with a matrix system and a stable NLC (nanostructured lipid carrier) delivery system and to determine drug release in vitro. Preparation of matrix system tablets using wet granulation method and NLC preparation using a combination of homogenization and ultrasonic methods. The results of this study obtained the optimum formula for matrix system tablets using PVP k-30 (3%), HPMC k-100 (37.18%), Mg. Stearate (0.5%) and Aerosil (0.5%), while NLC used Tween 80 (6%) and Pluracare F127 (2%) with glyceryl mono stearate as solid lipid and oleic acid as liquid lipid. The results of the matrix system tablet stability test are physically and chemically stable at storage temperatures of 25 ° C and 40 ° C. The in vitro activity test results showed that the matrix system tablet had similarity to the innovator, namely glucophage SR, with a similarity value in the phosphate buffer pH 6.8 66.13%, the citrate buffer pH 4.5 85.54% and 84.29%. in an HCl buffer pH 1.8. The sustained release formulation of metformin hydrochloride with a matrix and NLC system is stable and has an in vitro drug release similar to that of the innovator.